Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Mar 1;19(3):307-308.
doi: 10.1093/neuonc/now273.

The challenge of adequate imaging surveillance in primary central nervous system lymphoma

Affiliations
Comment

The challenge of adequate imaging surveillance in primary central nervous system lymphoma

Uwe Schlegel et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Hoang-Xuan K, Bessell E, Bromberg J, et al. ; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322–e332. - PubMed
    1. Abrey LE, Batchelor TT, Ferreri AJ, et al. ; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043. - PubMed
    1. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297–1303. - PMC - PubMed
    1. Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9(6):317–327. - PubMed
    1. Tabouret E, Houillier C, Martin-Duverneuil N, et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro Oncol. 2017;19(3):422–429. - PMC - PubMed